Home » Topics » Regulatory » EMA

EMA
RSS

Alexza provides regulatory update for Staccato Loxapine

Dec. 10, 2010

European approval of Brilique for prevention of atherothrombotic events

Dec. 10, 2010

UCB updates progress from third quarter of 2010

Dec. 1, 2010

FDA clears design of phase III oritavancin trials SOLO-1 and -2

Dec. 1, 2010

New Juvista formulation for children significantly improves scar appearance

Nov. 23, 2010

CIS Bio withdraws E.U. marketing authorization for NeoSpect

Nov. 23, 2010

EMA's COMP recommends orphan status for paquinimod in systemic sclerosis

Nov. 18, 2010

EMA accepts Pixuvri MAA for non-Hodgkin's lymphoma for review

Nov. 18, 2010

Roche reports on third quarter of 2010

Nov. 18, 2010

EMA approves Cell Therapeutics' pediatric investigation plan for Pixuvri

Nov. 17, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...